Robert M. Jones;Daniel J. Buzard;Sanju Narayanan;Sangdon Han;Juerg Lehmann;Dawei Yue
发明人:
Robert M. Jones,Sangdon Han,Daniel J. Buzard,Juerg Lehmann,Sanju Narayanan,Dawei Yue
申请号：
US13639652
公开号：
US20130023494A1
申请日:
2011.04.05
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single agent or in combination with one or more additional pharmaceutical agents, such as, an inhibitor of DPP-IV, a biguanide, an SGLT2 inhibitor, or an alpha-glucosidase inhibitor, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder； a condition ameliorated by increasing a blood incretin level； a metabolic-related disorder； type 2 diabetes； obesity； and complications related thereto.
